- Home
- RC vs GHRS Comparison
RC vs GHRS Comparison
Compare RC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RC
- GHRS
- Stock Information
- Founded
- RC 2007
- GHRS 2018
- Country
- RC United States
- GHRS Ireland
- Employees
- RC N/A
- GHRS N/A
- Industry
- RC Real Estate Investment Trusts
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- RC Real Estate
- GHRS Health Care
- Exchange
- RC Nasdaq
- GHRS Nasdaq
- Market Cap
- RC 907.7M
- GHRS 868.7M
- IPO Year
- RC N/A
- GHRS 2021
- Fundamental
- Price
- RC $5.03
- GHRS $10.70
- Analyst Decision
- RC Hold
- GHRS Strong Buy
- Analyst Count
- RC 8
- GHRS 7
- Target Price
- RC $7.58
- GHRS $30.86
- AVG Volume (30 Days)
- RC 4.2M
- GHRS 262.8K
- Earning Date
- RC 03-03-2025
- GHRS 05-02-2025
- Dividend Yield
- RC 18.61%
- GHRS N/A
- EPS Growth
- RC N/A
- GHRS N/A
- EPS
- RC N/A
- GHRS N/A
- Revenue
- RC N/A
- GHRS N/A
- Revenue This Year
- RC N/A
- GHRS N/A
- Revenue Next Year
- RC $7.26
- GHRS N/A
- P/E Ratio
- RC N/A
- GHRS N/A
- Revenue Growth
- RC N/A
- GHRS N/A
- 52 Week Low
- RC $4.74
- GHRS $6.00
- 52 Week High
- RC $9.54
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- RC 34.41
- GHRS 43.28
- Support Level
- RC $4.98
- GHRS $10.20
- Resistance Level
- RC $5.10
- GHRS $13.21
- Average True Range (ATR)
- RC 0.15
- GHRS 0.84
- MACD
- RC 0.05
- GHRS -0.03
- Stochastic Oscillator
- RC 29.49
- GHRS 14.98
About RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.